Literature DB >> 19027804

Structural properties of the ectodomain of hepatitis C virus E2 envelope protein.

Mar Rodríguez-Rodríguez1, Daniel Tello, Belén Yélamos, Julián Gómez-Gutiérrez, Beatriz Pacheco, Sara Ortega, Alicia G Serrano, Darrell L Peterson, Francisco Gavilanes.   

Abstract

We describe the structural and antigenic properties of a soluble form of hepatitis C virus E2 envelope protein ectodomain ending at residue 661 (E2(661)) which is obtained in large quantities in a baculovirus/insect cell system. The protein is secreted to the cellular medium by virus-infected cells. E2(661) is glycosylated and possesses a high tendency to self-associate. In fact, analytical ultracentrifugation and size exclusion chromatography studies show that the purified protein is mainly composed of dimers, trimers and tetramers being the dimer the smallest species present in solution. The secondary structure was determined by deconvolution of the far-UV circular dichroism spectrum yielding 8% alpha-helix structure, 47% extended structure and 45% non-ordered structure. The near-UV CD spectrum is indicative of a folded structure. The fluorescence emission spectrum indicates that Trp residues occupy a relatively low hydrophobic environment. Finally, E2(661) binds to a monoclonal conformation specific antibody and to antibodies present in human sera from HCV-positive patients. All these features suggest that the secreted protein possesses a native-like conformation. The use of this independent folding domain may contribute to shed light on the biology of HCV and could also be used as a vaccine in the prevention of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027804     DOI: 10.1016/j.virusres.2008.10.013

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  6 in total

1.  Expression and Ni-NTA-Agarose Purification of Recombinant Hepatitis C Virus E2Ectodomain Produced in a Baculovirus Expression System.

Authors:  Julián Gómez-Gutiérrez; Mar Rodríguez-Rodríguez; Francisco Gavilanes; Belén Yélamos
Journal:  Bio Protoc       Date:  2018-10-05

2.  In vitro Membrane Interaction and Liposome Fusion Assays Using Recombinant Hepatitis C Virus Envelope Protein E2.

Authors:  Belén Yélamos; Mar Rodríguez-Rodríguez; Francisco Gavilanes; Julián Gómez-Gutiérrez
Journal:  Bio Protoc       Date:  2018-12-05

3.  Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain.

Authors:  Jillian Whidby; Guaniri Mateu; Hannah Scarborough; Borries Demeler; Arash Grakoui; Joseph Marcotrigiano
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

4.  Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.

Authors:  Reem R Al Olaby; Laurence Cocquerel; Adam Zemla; Laure Saas; Jean Dubuisson; Jost Vielmetter; Joseph Marcotrigiano; Abdul Ghafoor Khan; Felipe Vences Catalan; Alexander L Perryman; Joel S Freundlich; Stefano Forli; Shoshana Levy; Rod Balhorn; Hassan M Azzazy
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

5.  A Biologically-validated HCV E1E2 Heterodimer Structural Model.

Authors:  Matteo Castelli; Nicola Clementi; Jennifer Pfaff; Giuseppe A Sautto; Roberta A Diotti; Roberto Burioni; Benjamin J Doranz; Matteo Dal Peraro; Massimo Clementi; Nicasio Mancini
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

6.  Inflammatory response of endothelial cells to hepatitis C virus recombinant envelope glycoprotein 2 protein exposure.

Authors:  Ana Carolina Urbaczek; Lívia Carolina de Abreu Ribeiro; Valdecir Farias Ximenes; Ana Afonso; Camila Tita Nogueira; Wesley Cardoso Generoso; Juliana Vieira Alberice; Martina Rudnicki; Renila Ferrer; Luiz Marcos da Fonseca; Paulo Inácio da Costa
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-09-09       Impact factor: 2.743

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.